Gift or transfer — classified separately from trades.
Traded Aug 17, 2026 · Filed Aug 18, 2026
Eli Lilly's & President, LLY Int'l sold $7.64M of Eli Lilly shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$7,638,150
Shares × reported transaction price
12 days after results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1,183.16 on Aug 17, 2026, within 5% of its 52-week high, after a 1% drop over the previous 30 trading days
52-week range $695.33 (Aug 25, 2025) to $1,235.56 (Jul 7, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $1,200.06 on Jul 6, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Zepbound on Aug 26, 2026, 9 days after this trade.
New use approved (efficacy supplement). Active ingredient: Tirzepatide. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -7.1% | -0.4% | -6.7% |
| 30 days | -9.9% | -1.0% | -9.0% |
Past results only. Not a forecast.
Gift or transfer — classified separately from trades.
Gift or transfer — classified separately from trades.
Gift or transfer — classified separately from trades.